Barclays PLC Has $150,000 Stake in INmune Bio, Inc. (NASDAQ:INMB)

Barclays PLC raised its position in INmune Bio, Inc. (NASDAQ:INMB) by 10.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 32,019 shares of the company’s stock after purchasing an additional 2,975 shares during the period. Barclays PLC’s holdings in INmune Bio were worth $150,000 as of its most recent filing with the SEC.

A number of other hedge funds have also added to or reduced their stakes in INMB. Raymond James Financial Inc. purchased a new position in INmune Bio during the fourth quarter worth about $2,221,000. Geode Capital Management LLC boosted its stake in INmune Bio by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 363,602 shares of the company’s stock worth $1,698,000 after buying an additional 19,136 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of INmune Bio by 73.3% in the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company’s stock valued at $868,000 after acquiring an additional 78,600 shares during the last quarter. Westside Investment Management Inc. raised its stake in shares of INmune Bio by 26.2% during the fourth quarter. Westside Investment Management Inc. now owns 89,975 shares of the company’s stock valued at $420,000 after acquiring an additional 18,660 shares during the last quarter. Finally, Fermata Advisors LLC lifted its holdings in INmune Bio by 10.0% in the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock worth $219,000 after buying an additional 4,267 shares during the period. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Trading Up 5.5%

Shares of INMB stock opened at $8.06 on Wednesday. The company has a market cap of $185.25 million, a PE ratio of -3.70 and a beta of 1.63. The business’s fifty day simple moving average is $7.67 and its 200-day simple moving average is $6.90. INmune Bio, Inc. has a 12-month low of $4.32 and a 12-month high of $11.47.

INmune Bio (NASDAQ:INMB) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $0.05 million for the quarter. On average, equities analysts forecast that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on INMB shares. RODMAN&RENSHAW upgraded shares of INmune Bio to a “strong-buy” rating in a report on Tuesday, January 28th. Rodman & Renshaw initiated coverage on shares of INmune Bio in a research note on Tuesday, January 28th. They set a “buy” rating and a $23.00 target price for the company. Maxim Group lifted their target price on INmune Bio from $22.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Scotiabank raised their price target on shares of INmune Bio from $22.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, February 11th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.